{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:25:27Z","timestamp":1785522327853,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03633-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:39:57Z","timestamp":1779529197000},"page":"3660-3673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis\u00a0B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct06923280","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qiran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuncheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"3633_CR1","unstructured":"World Health Organization. Global hepatitis report 2024 1st ed. Geneva: World Health Organization. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240091672 Accessed 9 April 2024."},{"key":"3633_CR2","unstructured":"National Disease Control and Prevention Administration. National epidemic situation of notifiable infectious diseases in 2024. 2025. https:\/\/www.ndcpa.gov.cn\/jbkzzx\/c100016\/common\/content\/content_1998217472895258624.html Accessed 9 Dec 2025."},{"key":"3633_CR3","volume":"51","author":"Z Hui","year":"2024","unstructured":"Hui Z, Yu W, Fuzhen W, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health Eur. 2024;51:101193.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"3633_CR4","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis\u00a0B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"3633_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001549","author":"MG Ghany","year":"2025","unstructured":"Ghany MG, Pan CQ, Lok AS, et al. AASLD\/IDSA practice guideline on treatment of chronic hepatitis\u00a0B. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001549.","journal-title":"Hepatology"},{"issue":"2","key":"3633_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis\u00a0B virus infection. J Hepatol. 2025;83(2):502\u201383.","journal-title":"J Hepatol"},{"issue":"Suppl","key":"3633_CR7","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.3350\/cmh.2024.0780","volume":"31","author":"D Wu","year":"2025","unstructured":"Wu D, Kao JH, Piratvisuth T, et al. Update on the treatment navigation for functional cure of chronic hepatitis\u00a0B: expert consensus 2.0. Clin Mol Hepatol. 2025;31(Suppl):S134\u201364.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"3633_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis\u00a0B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12(4):341\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"3633_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"issue":"10","key":"3633_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, et al. Roadmap to functional cure of chronic hepatitis\u00a0B: an expert consensus. J Viral Hepat. 2019;26(10):1146\u201355.","journal-title":"J Viral Hepat"},{"issue":"1","key":"3633_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12951-024-03004-3","volume":"22","author":"L Nguyen","year":"2024","unstructured":"Nguyen L, Nguyen TT, Kim JY, Jeong JH. Advanced siRNA delivery in combating hepatitis\u00a0B virus: mechanistic insights and recent updates. J Nanobiotechnol. 2024;22(1):745.","journal-title":"J Nanobiotechnol"},{"issue":"10","key":"3633_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","volume":"27","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis\u00a0B: a phase\u00a02 randomized controlled trial. Nat Med. 2021;27(10):1725\u201334.","journal-title":"Nat Med"},{"issue":"4","key":"3633_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","volume":"79","author":"E Gane","year":"2023","unstructured":"Gane E, Lim YS, Kim JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis\u00a0B: Results from randomized clinical trials. J Hepatol. 2023;79(4):924\u201332.","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"3633_CR14","first-page":"S203","volume":"75","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Berliba E, Sukeepaisarnjaroen W, et al. Repeat dosing of the GaINAc-siRNA AB-729 in subjects with chronic hepatitis\u00a0B results in robust and sustained HBsAg suppression. J Hepatol. 2021;75(Suppl 2):S203\u20134.","journal-title":"J Hepatol"},{"issue":"3","key":"3633_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","volume":"81","author":"K Agarwal","year":"2024","unstructured":"Agarwal K, Buti M, van B\u00f6mmel F, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis\u00a0B: REEF-2. J Hepatol. 2024;81(3):404\u201314.","journal-title":"J Hepatol"},{"issue":"21","key":"3633_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis\u00a0B infection. N Engl J Med. 2022;387(21):1957\u201368.","journal-title":"N Engl J Med"},{"key":"3633_CR17","unstructured":"Niu JQ, Ding YH, Liang XE, et al. High proportion of participants achieved sustained complete response 24\u00a0weeks after end of AHB-137 treatment in HBeAg negative chronic hepatitis\u00a0B participants on NA therapy: pooled analysis of two phase\u00a02 studies in China. AASLD 2025, Late-Breaking Abstract 5022."},{"issue":"4","key":"3633_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-025-10823-5","volume":"19","author":"J Chen","year":"2025","unstructured":"Chen J, Ji D, Jia J, et al. Functional cure with new antiviral therapy for hepatitis\u00a0B virus: a systematic review and meta-analysis. Hepatol Int. 2025;19(4):773\u201395.","journal-title":"Hepatol Int"},{"issue":"6","key":"3633_CR19","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s12072-021-10262-y","volume":"15","author":"HY Chon","year":"2021","unstructured":"Chon HY, Ahn SH, Kim YJ, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis\u00a0B patients. Hepatol Int. 2021;15(6):1328\u201336.","journal-title":"Hepatol Int"},{"issue":"1","key":"3633_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","volume":"76","author":"S Fung","year":"2022","unstructured":"Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76(1):233\u201350.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"3633_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/liv.12735","volume":"35","author":"M Martinot-Peignoux","year":"2015","unstructured":"Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic Hepatitis\u00a0B patients. Liver Int. 2015;35(Suppl 1):82\u201390.","journal-title":"Liver Int"},{"issue":"22","key":"3633_CR22","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","volume":"391","author":"J Hou","year":"2024","unstructured":"Hou J, Zhang W, Xie Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis\u00a0B. N Engl J Med. 2024;391(22):2098\u2013109.","journal-title":"N Engl J Med"},{"issue":"12","key":"3633_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","volume":"9","author":"MF Yuen","year":"2024","unstructured":"Yuen MF, Lim YS, Yoon KT, et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis\u00a0B virus infection: a phase\u00a02 study. Lancet Gastroenterol Hepatol. 2024;9(12):1121\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3633_CR24","unstructured":"Pegberon\u00ae (Peginterferon alfa-2b injection) [package insert]. China: Amoytop Biotech; 2017."},{"issue":"2","key":"3633_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","volume":"82","author":"M Buti","year":"2025","unstructured":"Buti M, Heo J, Tanaka Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis\u00a0B. J Hepatol. 2025;82(2):222\u201334.","journal-title":"J Hepatol"},{"issue":"3","key":"3633_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/gutjnl-2024-333026","volume":"74","author":"LY Mak","year":"2025","unstructured":"Mak LY, Wooddell CI, Lenz O, et al. Long-term hepatitis\u00a0B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 2025;74(3):440\u201350.","journal-title":"Gut"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03633-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03633-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03633-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:04Z","timestamp":1785518044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03633-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03633-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Ln, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie and Wenhong Zhang confirm that they have no competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki guidelines for human research. The protocol has been approved by the institutional review board (IRB) at each site. \u00a0Written informed consent is obtained from all participants prior to enrolment, during which researchers will explain the nature of the study, procedures, risks, benefits and the right to withdraw to each participant,\u00a0and identification will remain confidential according to ethical principles of confidentiality and privacy. The trial is registered at ClinicalTrials.gov (NCT06923280). Results will be submitted for publication in peer-reviewed journals.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study concept arose from clinical observations of HBsAg rebound after RNA-interference trials, and was not initiated at the request of any specific patient. The participants were not involved in study design, recruitment or conduct. Results will be disseminated via peer-reviewed publications to participants.","order":3,"name":"Ethics","label":"Patient and Public Involvement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}